Clinical trials
Phase 3 Low Back Pain trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
53 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 6 |
| 2005 | 1 |
| 2006 | 4 |
| 2007 | 4 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 5 |
| 2012 | 7 |
| 2013 | 3 |
| 2015 | 6 |
| 2017 | 1 |
| 2018 | 2 |
| 2021 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 44 |
| Terminated | 3 |
| Unknown status | 3 |
| Active, not recruiting | 1 |
| Recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Purdue Pharma LP | 7 |
| BioDelivery Sciences International | 6 |
| Kaiser Permanente | 3 |
| Pfizer | 3 |
| Teva Branded Pharmaceutical Products R&D, Inc. | 3 |
| Endo USA Inc., a Keenova Therapeutics Company | 2 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2 |
| Meda Pharmaceuticals | 2 |
| Montefiore Medical Center | 2 |
| Nektar Therapeutics | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Low Back Pain | 53 |
| Chronic Pain | 15 |
| Pain | 10 |
| Back Pain | 9 |
| Osteoarthritis | 8 |
| Intervertebral Disc Degeneration | 3 |
| Neuralgia | 3 |
| Agnosia | 2 |
| Constipation | 2 |
| Acute Pain | 1 |
Trials
Showing 1 to 25 of 53. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.